Corcept Therapeutics (CORT)
NASDAQ: CORT
· Real-Time Price · USD
77.54
-0.10 (-0.13%)
At close: May 30, 2025, 3:59 PM
77.75
0.27%
After-hours: May 30, 2025, 05:13 PM EDT
-0.13% (1D)
| Bid | 76.5 |
| Market Cap | 8.22B |
| Revenue (ttm) | 685.45M |
| Net Income (ttm) | 132.85M |
| EPS (ttm) | 1.15 |
| PE Ratio (ttm) | 67.43 |
| Forward PE | 29.17 |
| Analyst | Strong Buy |
| Ask | 79 |
| Volume | 760,281 |
| Avg. Volume (20D) | 1,628,917 |
| Open | 77.64 |
| Previous Close | 77.64 |
| Day's Range | 75.23 - 78.67 |
| 52-Week Range | 28.04 - 117.33 |
| Beta | 0.21 |
About CORT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CORT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CORT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-4.33%
Corcept Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
3 weeks ago
+1.61%
Corcept Therapeutics shares are trading lower after the company reported a Q1 sales miss.
3 weeks ago · seekingalpha.com
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call TranscriptCorcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrino...
1 month ago · seekingalpha.com
Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings MissDespite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potenti...
